Alzinova AB (78D) AI Stock Analysis

Alzinova AB

(Frankfurt:78D)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageMinimal debt and extremely low leverage reduce fixed financial obligations while the company advances its clinical programs. This gives Alzinova greater flexibility to allocate capital toward research and development and lowers balance-sheet pressure during periods of continued operating losses.

Negative Factors

Persistent operating lossesDeeply negative operating profit and net income show that Alzinova remains far from breakeven while funding development activities. Persistent losses limit internally generated capital, increase dependence on financing or partnerships, and make future profitability dependent on successful clinical and commercial progress.

Alzinova AB (78D) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 10.22M
Dividend Yield: ―
Average Volume (3M): 11.98K
Price to Earnings (P/E): -1.7
Beta (1Y): 1.62
Revenue Growth: -100.00%
EPS Growth: 18.26%
Country: Germany
Employees: 7
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Alzinova AB Business Overview & Revenue Model

Company Description

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alz...

Alzinova AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:78D against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SANION	77Outperform	SEK 1.54B	8.30	29.71%	―	24.98%	-31.44%
SE:BIOA.B	65Neutral	SEK 28.15B	266.55	5.18%	0.68%	-46.09%	-90.13%
SE:ALZCUR	55Neutral	SEK 882.54M	42.87	65.99%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ACTI	42Neutral	SEK 105.31M	-10.14	-93.01%	―	―	54.60%
SE:IRLAB.A	42Neutral	SEK 310.81M	-3.21	-97.06%	―	4.74%	66.33%

* Healthcare Sector Average

Performance Comparison

DE:78D and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:78D	Alzinova AB	0.02	-0.08	-79.05%
SE:ALZCUR	AlzeCure Pharma AB	6.40	4.51	238.45%
SE:BIOA.B	BioArctic AB Class B	317.20	36.66	13.07%
SE:SANION	Saniona AB	11.13	-4.73	-29.82%
SE:IRLAB.A	IRLAB Therapeutics AB Class A	2.09	-0.40	-15.90%
SE:ACTI	Active Biotech AB	4.00	-2.42	-37.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Alzinova AB AI Stock Analysis